MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.
Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS.
Tang C, et al. Among authors: kurzrock r.
Oncoscience. 2013 Dec 11;1(1):5-13. doi: 10.18632/oncoscience.3. eCollection 2014.
Oncoscience. 2013.
PMID: 25593979
Free PMC article.